2008 turned out to be an exciting and important year for completing large drug discovery milestones at Nutra Pharma.  As the year quickly comes to a close, I wanted to take a moment to reflect back on our top accomplishments… Medical Devices We began developing and marketing through our medical devices subsidiary, Designer Diagnostics, the [...]

Read Full Post »

For the past week, we have fielded several phone calls and emails asking us about the status of our clinical data for our Phase IIb study in treating Adrenomyeloneuropathy (AMN). While we are working diligently to get this information compiled, analyzed, and published as quickly as possible, it has taken a little longer than expected [...]

Read Full Post »

In 1983, the United States Congress passed legislation, known as the Orphan Drug Act, to incentivize companies to develop drugs for diseases with prevalence rates of less than 200,000 patients in the United States. Having such low prevalence rates, these diseases were defined in the Act as “rare diseases” or “orphan diseases”. Prior to the [...]

Read Full Post »

For the past several weeks, we’ve been updating our 2008 Corporate Presentation. It’s finally complete and we’re excited to share it with you. Feel free to download a copy of the Presentation by clicking on the image above or by clicking here. (Adobe Acrobat Reader is required to view this document. If you do not have Adobe [...]

Read Full Post »

Dear Fellow Shareholders of Nutra Pharma: As the Chairman, Chief Executive Officer, and fellow investor in the Company, I am excited and pleased to share with you the recent progress we have made in our drug research. Last week marked one of the most exciting accomplishments for our company. As many of you read in [...]

Read Full Post »